Opgen, Inc. (OPGN)

Trade OPGN now with
10/7/2019 7:59:03 AM OpGen Presents Preliminary Acuitas AMR Gene Panel Data For Detecting Urinary Tract Infections
5/14/2019 7:36:00 AM OpGen Completes Initial FDA 510(k) Submission For Acuitas AMR Gene Panel Test
2/25/2019 8:40:45 AM OpGen Appoints Don Elsey To Board
2/5/2019 7:33:50 AM OpGen Completes Clinical Trials For Its Initial FDA 510(k) Submission
12/4/2018 7:33:32 AM OpGen Receives Regulatory Approval To Market Pathogen Identification Products In Colombia
10/31/2018 7:35:55 AM OpGen Partners With QIAGEN To Advance Rapid Diagnostics For Antimicrobial Resistant Bacteria
10/18/2018 8:16:41 AM OpGen Reports Pricing Of Public Offering Of About 2.2 Mln Shares At $1.45/Shr
6/14/2018 8:32:04 AM OpGen Modifies Terms Of Debt With Merck Global Health Innovation Fund
3/13/2018 7:38:24 AM OpGen Partners With BIDMC In Boston On A Verification Study For Acuitas Test
2/13/2018 7:33:01 AM OpGen Enters Global Supply Deal To Use Thermo Fisher Scientific’s PCR Technology In Acuitas AMR Gene Panel Tests
2/7/2018 7:34:09 AM OpGen Announces Closing Of $12 Mln Public Offering
7/13/2017 6:02:13 AM OpGen Prices Public Offering Of 25 Mln Units At $0.40/unit
6/19/2017 8:09:54 AM OpGen Signs Supply Agreement To Use Thermo Fisher Scientific’s Technology To Advance Acuitas Rapid Test